354 related articles for article (PubMed ID: 28894700)
1. Targeting the Type II Secretion System: Development, Optimization, and Validation of a High-Throughput Screen for the Identification of Small Molecule Inhibitors.
Waack U; Johnson TL; Chedid K; Xi C; Simmons LA; Mobley HLT; Sandkvist M
Front Cell Infect Microbiol; 2017; 7():380. PubMed ID: 28894700
[TBL] [Abstract][Full Text] [Related]
2. Comparative proteomics analyses of Acinetobacter baumannii strains ATCC 17978 and AB5075 reveal the differential role of type II secretion system secretomes in lung colonization and ciprofloxacin resistance.
Elhosseiny NM; Elhezawy NB; Attia AS
Microb Pathog; 2019 Mar; 128():20-27. PubMed ID: 30578836
[TBL] [Abstract][Full Text] [Related]
3. Development, Optimization, and Validation of a High Throughput Screening Assay for Identification of Tat and Type II Secretion Inhibitors of
Massai F; Saleeb M; Doruk T; Elofsson M; Forsberg Å
Front Cell Infect Microbiol; 2019; 9():250. PubMed ID: 31355152
[TBL] [Abstract][Full Text] [Related]
4. The secretome of Acinetobacter baumannii ATCC 17978 type II secretion system reveals a novel plasmid encoded phospholipase that could be implicated in lung colonization.
Elhosseiny NM; El-Tayeb OM; Yassin AS; Lory S; Attia AS
Int J Med Microbiol; 2016 Dec; 306(8):633-641. PubMed ID: 27713027
[TBL] [Abstract][Full Text] [Related]
5. Acinetobacter baumannii Is Dependent on the Type II Secretion System and Its Substrate LipA for Lipid Utilization and In Vivo Fitness.
Johnson TL; Waack U; Smith S; Mobley H; Sandkvist M
J Bacteriol; 2015 Dec; 198(4):711-9. PubMed ID: 26668261
[TBL] [Abstract][Full Text] [Related]
6. InvL, an Invasin-Like Adhesin, Is a Type II Secretion System Substrate Required for Acinetobacter baumannii Uropathogenesis.
Jackson-Litteken CD; Di Venanzio G; Le NH; Scott NE; Djahanschiri B; Distel JS; Pardue EJ; Ebersberger I; Feldman MF
mBio; 2022 Jun; 13(3):e0025822. PubMed ID: 35638734
[TBL] [Abstract][Full Text] [Related]
7. The Secrets of Acinetobacter Secretion.
Weber BS; Kinsella RL; Harding CM; Feldman MF
Trends Microbiol; 2017 Jul; 25(7):532-545. PubMed ID: 28216293
[TBL] [Abstract][Full Text] [Related]
8. Screening of small molecules attenuating biofilm formation of Acinetobacter baumannii by inhibition of ompA promoter activity.
Na SH; Jeon H; Oh MH; Kim YJ; Lee JC
J Microbiol; 2021 Sep; 59(9):871-878. PubMed ID: 34449059
[TBL] [Abstract][Full Text] [Related]
9. Fluorescence High-Throughput Screening for Inhibitors of TonB Action.
Nairn BL; Eliasson OS; Hyder DR; Long NJ; Majumdar A; Chakravorty S; McDonald P; Roy A; Newton SM; Klebba PE
J Bacteriol; 2017 May; 199(10):. PubMed ID: 28242720
[TBL] [Abstract][Full Text] [Related]
10. The structure of
Urusova DV; Kinsella RL; Salinas ND; Haurat MF; Feldman MF; Tolia NH
J Biol Chem; 2019 Sep; 294(36):13344-13354. PubMed ID: 31320476
[TBL] [Abstract][Full Text] [Related]
11. Medically Relevant Acinetobacter Species Require a Type II Secretion System and Specific Membrane-Associated Chaperones for the Export of Multiple Substrates and Full Virulence.
Harding CM; Kinsella RL; Palmer LD; Skaar EP; Feldman MF
PLoS Pathog; 2016 Jan; 12(1):e1005391. PubMed ID: 26764912
[TBL] [Abstract][Full Text] [Related]
12. The Glycoprotease CpaA Secreted by Medically Relevant Acinetobacter Species Targets Multiple
Haurat MF; Scott NE; Di Venanzio G; Lopez J; Pluvinage B; Boraston AB; Ferracane MJ; Feldman MF
mBio; 2020 Oct; 11(5):. PubMed ID: 33024038
[TBL] [Abstract][Full Text] [Related]
13. Microbiological features and clinical impact of the type VI secretion system (T6SS) in Acinetobacter baumannii isolates causing bacteremia.
Kim J; Lee JY; Lee H; Choi JY; Kim DH; Wi YM; Peck KR; Ko KS
Virulence; 2017 Oct; 8(7):1378-1389. PubMed ID: 28448786
[TBL] [Abstract][Full Text] [Related]
14. New Multidrug Efflux Inhibitors for Gram-Negative Bacteria.
Marshall RL; Lloyd GS; Lawler AJ; Element SJ; Kaur J; Ciusa ML; Ricci V; Tschumi A; Kühne H; Alderwick LJ; Piddock LJV
mBio; 2020 Jul; 11(4):. PubMed ID: 32665275
[TBL] [Abstract][Full Text] [Related]
15. Native and Foreign Proteins Secreted by the
Xu H; Denny TP
J Microbiol Biotechnol; 2017 Apr; 27(4):791-807. PubMed ID: 28119513
[TBL] [Abstract][Full Text] [Related]
16. Complexity of Complement Resistance Factors Expressed by
Sanchez-Larrayoz AF; Elhosseiny NM; Chevrette MG; Fu Y; Giunta P; Spallanzani RG; Ravi K; Pier GB; Lory S; Maira-Litrán T
J Immunol; 2017 Oct; 199(8):2803-2814. PubMed ID: 28855313
[No Abstract] [Full Text] [Related]
17. The small molecule IITR08027 restores the antibacterial activity of fluoroquinolones against multidrug-resistant Acinetobacter baumannii by efflux inhibition.
Bhattacharyya T; Sharma A; Akhter J; Pathania R
Int J Antimicrob Agents; 2017 Aug; 50(2):219-226. PubMed ID: 28533185
[TBL] [Abstract][Full Text] [Related]
18. Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model.
Lood R; Winer BY; Pelzek AJ; Diez-Martinez R; Thandar M; Euler CW; Schuch R; Fischetti VA
Antimicrob Agents Chemother; 2015 Apr; 59(4):1983-91. PubMed ID: 25605353
[TBL] [Abstract][Full Text] [Related]
19. Acinetobacter baumannii: biology and drug resistance - role of carbapenemases.
Nowak P; Paluchowska P
Folia Histochem Cytobiol; 2016; 54(2):61-74. PubMed ID: 27270503
[TBL] [Abstract][Full Text] [Related]
20. Acinetobacter baumannii OxPhos inhibitors as selective anti-infective agents.
Rubin H; Selwood T; Yano T; Weaver DG; Loughran HM; Costanzo MJ; Scott RW; Wrobel JE; Freeman KB; Reitz AB
Bioorg Med Chem Lett; 2015 Jan; 25(2):378-83. PubMed ID: 25496770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
